- An analyst at Needham has increased the price target for Veracyte (NASDAQ: VCYT) to $57.00, reflecting strong confidence in the company.
- Key drivers for the positive outlook include the successful U.S. launch of the Prosigna Breast Risk of Recurrence test and favorable data from the Decipher Prostate test.
- The company’s stock is demonstrating strong performance, trading at $48.68 and nearing its 52-week high of $50.71, indicating robust market sentiment.
On June 1, 2026, an analyst at Needham increased the price target for Veracyte (NASDAQ: VCYT) to $57.00. At the time, the biotechnology stock’s price was $48.38, suggesting a potential gain of 17.81%. Veracyte is a company focused on developing and selling advanced cancer diagnostic tests.
Veracyte has a market capitalization of approximately $3.88 billion. Market capitalization is the total value of a company’s shares. The positive analyst outlook for this diagnostic company follows key announcements, including the U.S. launch of its Prosigna Breast Risk of Recurrence test, as highlighted by Business Wire.
The Prosigna test helps doctors and patients with early-stage breast cancer decide on treatment options. It utilizes genetics to determine if a patient can safely avoid chemotherapy, a crucial aspect of personalized medicine. This is based on results from the landmark OPTIMA trial, which showed the test can effectively guide these important treatment decisions.
The company also announced positive results for its Decipher Prostate test, a significant advancement in prostate cancer diagnosis. Data from the ENZAMET trial shows the test can identify which men with metastatic prostate cancer benefit from adding chemotherapy. This is a significant development for the roughly 334 thousand men diagnosed with prostate cancer, offering new avenues for targeted treatment.
Reflecting these developments, Veracyte’s stock is trading at $48.68, a daily gain of 5.06%. The stock’s price is near its 52-week high of $50.71, having traded up from a low of $22.61. This demonstrates strong stock performance over the past year for the diagnostic firm.
